🔎 Trials Near Me

Acasă › Cancer ovarian › Ohio

Studii clinice pentru Cancer ovarian în Ohio

70 studii pentru Cancer ovarian caută participanți în Ohio.

Orașe în Ohio

Text oficial al studiului (în engleză)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • OhioHealth O'Bleness Hospital, Athens
  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • și încă 39
În curs de recrutareFaza 2
Toate vârstele · Toate sexele · Actualizat 2 oct. 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • The Cleveland Clinic Taussig Cancer Center, Cleveland
În curs de recrutareFaza 1/2
Vârste de 12 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT04585750

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University Hospitals Cleveland Medical Center, Cleveland
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT06465069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Cleveland Clinic - Oncology Department, Cleveland
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT06760819

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

  • University of Cincinnati Medical Center. /ID# 278925, Cincinnati
  • University Hospitals Cleveland Medical Center /ID# 279601, Cleveland
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Femei · Actualizat 1 oct. 2026 · NCT07024784

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

  • Research Site, Cleveland
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Femei · Actualizat 1 oct. 2026 · NCT07851025

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati
  • Site 0243 - Mark H Zangmeister Cancer Center, Columbus
  • Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Femei · Actualizat 29 sept. 2026 · NCT05128825

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
  • Cleveland Clinic - Cleveland /ID# 276133, Cleveland
  • Cleveland Clinic - Cleveland /ID# 278273, Cleveland
  • și încă 3
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Femei · Actualizat 29 sept. 2026 · NCT06890338

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Cleveland Clinic, Cleveland
În curs de recrutareStudiu observațional
Vârste de 18 ani și peste · Femei · Actualizat 29 sept. 2026 · NCT05051722

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Cleveland
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT05867251

DESTINY-PANTUMOUR04

  • Research Site, Canton
  • Research Site, Maumee
În curs de recrutareStudiu observațional
Vârste de la 18 la 130 · Toate sexele · Actualizat 25 sept. 2026 · NCT07124000

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • The Ohio State University Comprehensive Cancer Center, Columbus
În curs de recrutareStudiu observațional
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT04981119

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

  • The Ohio State University Wexner Medical Center, Columbus
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Femei · Actualizat 25 sept. 2026 · NCT03564340

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  • The Ohio State University Wexner Medical Center, Columbus
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Femei · Actualizat 24 sept. 2026 · NCT04590326

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Cincinnati
  • Research Site, Columbus
În curs de recrutareFaza 2
Vârste de la 18 la 130 · Toate sexele · Actualizat 23 sept. 2026 · NCT05489211

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  • Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Femei · Actualizat 22 sept. 2026 · NCT07059845

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Miami Valley Hospital South, Centerville
  • University of Cincinnati Medical Center, Cincinnati
  • Oncology Hematology Care Inc, Cincinnati
  • și încă 7
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07213804

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • UH Cleveland Medical Center, Cleveland
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 17 sept. 2026 · NCT07109726

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • University of Cincinnati Medical Center ( Site 0042), Cincinnati
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Femei · Actualizat 17 sept. 2026 · NCT07318558

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Oncology Hematology Care, Inc, Cincinnati
  • The Mark H Zangmeister Cancer Center Ohio, Columbus
  • The Ohio State University Wexner Medical Center Division of Gynecologic Oncology, Hilliard
În curs de recrutareFaza 2
Vârste de la 18 la 99 · Femei · Actualizat 15 sept. 2026 · NCT07023627

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Cleveland Clinic Foundation, Cleveland
  • Ohio Health Research Institute, Columbus
  • Miami Valley Hospital South, Dayton
  • și încă 1
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Femei · Actualizat 15 sept. 2026 · NCT07214779

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • Christ Hospital, Cincinnati
  • Ohio State University, Columbus
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 14 sept. 2026 · NCT06303505

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

  • Cleveland Clinic, Cleveland
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Femei · Actualizat 14 sept. 2026 · NCT04575935

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  • The Ohio State University Comprehensive Cancer Center, Hilliard
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Femei · Actualizat 14 sept. 2026 · NCT06787612

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Cleveland Clinic, Cleveland
  • Toledo Clinic Cancer Center, Toledo
În curs de recrutareStudiu observațional
Vârste de 18 ani și peste · Toate sexele · Actualizat 14 sept. 2026 · NCT05059444

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  • Miami Valley Hospital South, Centerville
  • Zangmeister Cancer Center, Columbus
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Femei · Actualizat 9 sept. 2026 · NCT07225270

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • The Ohio State University (OSU) Wexner Medical Center, Columbus
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 4 sept. 2026 · NCT06400472

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  • University of Cincinnati Medical Center ( Site 0090), Cincinnati
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Femei · Actualizat 3 sept. 2026 · NCT06824467

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Louis Stokes Cleveland VA Medical Center, Cleveland
În curs de recrutareVoluntari sănătoși bineveniți
Vârste de la 45 la 75 · Toate sexele · Actualizat 2 sept. 2026 · NCT06995898

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

  • Cleveland Clinic, Cleveland
  • OhioHealth Research Institute, Columbus
  • Kettering Health, Kettering
  • și încă 1
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Femei · Actualizat 26 aug. 2026 · NCT05281471

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • The Ohio State University, Columbus
În curs de recrutareFaza 1
Vârste de 15 ani și peste · Toate sexele · Actualizat 25 aug. 2026 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Cincinnati Children's Hospital Medical Center, Cincinnati
În curs de recrutareFaza 1/2
12 Months – 30 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT04851119

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Cleveland Clinic Taussig Cancer Institute, Cleveland
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 21 aug. 2026 · NCT06774963

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  • Research Site, Columbus
În curs de recrutareFaza 1/2
Vârste de la 18 la 130 · Toate sexele · Actualizat 21 aug. 2026 · NCT05797168

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Ohio State University Comprehensive Cancer Center, Columbus
În curs de recrutareFaza 2/3
Vârste de 18 ani și peste · Toate sexele · Actualizat 19 aug. 2026 · NCT07001748

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Maumee
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 18 aug. 2026 · NCT07182149

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  • Ohio State University Wexner Medical Center, Columbus
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 18 aug. 2026 · NCT07470853

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

  • Ohio State University Comprehensive Cancer Center, Columbus
În curs de recrutareFaza 1 timpurie
Vârste de 18 ani și peste · Femei · Actualizat 17 aug. 2026 · NCT07144826

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

  • The Ohio State University, Columbus
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 13 aug. 2026 · NCT05985655

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.